Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$8.73 USD
+0.29 (3.44%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $8.72 -0.01 (-0.11%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IOVA 8.73 +0.29(3.44%)
Will IOVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOVA
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Other News for IOVA
Buy Rating Affirmed on Iovance Biotherapeutics Amidst Positive European and Global Prospects for Lifileucel
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics submits MAA to EMA for lifileucel
Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jefferies healthcare analyst holds an analyst/industry conference call